Transplantation outcome and molecular monitoring of residual disease
| Patient . | Diagnosis . | Acute GVHD grade . | Chronic GVHD . | Status d +60 . | MRD d +60 . | Current status/PCR (d) . | Cause of death . |
|---|---|---|---|---|---|---|---|
| 1 | CLL | 1 | Abs | PR | NA | PD (700) | — |
| 2 | CLL | 1 | Lim | CR | Pos | CR/MD (310) | — |
| 3 | CLL | 0 | Abs | CR | Na | CR/MR (130) | — |
| 4 | CLL | 2 | Lim | CR | Neg | CR/MR (380) | — |
| 5 | Waldens | 0 | Abs | SD | NA | SD (220) | — |
| 6 | MZL | 3 | Ext | PR | NA | Dead (234) | Pneumonia/GVHD |
| 7 | FCL | 0 | Abs | CR | Neg | CR/MR (755) | — |
| 8 | FCL | 2 | Abs | CR | Neg | CR/MR (510) | — |
| 9 | FCL | 2* | Ext | CR | Pos | CR/MR (485) | — |
| 10 | MCL | 2 | Abs | PR | Na | Dead (188) | Lymphoma |
| 11 | MCL | 2 | Ext | PR | Na | Dead (698) | Lymphoma |
| 12 | MCL | 3 | Ext | PR | Na | CR (160) | — |
| 13 | MCL | 2 | Ext | CR | Neg | CR/MR (850) | — |
| 14 | DLCL | 1 | Lim | CR | Neg | CR/MR (735) | — |
| 15 | DLCL | 0 | Abs | CR | — | CR (220) | — |
| 16 | DLCL | 1 | Abs | CR | — | PD (490) | — |
| 17 | DLCL | 1 | Abs | CR | — | CR (440) | — |
| 18 | T cell | 2 | Abs | CR | — | CR (340) | — |
| 19 | DLCL | 2 | Na | NA | Na | Dead (69) | TTP |
| 20 | DLCL | 0 | Abs | CR | Na | CR (180) | — |
| 21 | BL | 0 | Abs | CR | Neg | CR/MR (250) | — |
| 22 | DLCL | 1 | Na | PR | Na | Dead (95) | Lymphoma |
| 23 | DLCL | 2 | Lim | CR | — | CR (850) | — |
| 24 | DLCL | 1 | Lim | CR | Neg | CR/MR (850) | — |
| 25 | HD | 1 | Lim | SD | Na | Dead (240) | Hodgkin |
| 26 | HD | 0 | Abs | PD | Na | PD (170) | — |
| 27 | HD | 0 | Ext | SD | Na | PD (600) | Hodgkin |
| 28 | HD | 2* | Lim | CR | — | CR (410) | — |
| 29 | MM | 4 | Ext | PR | Na | Dead (140) | GVHD |
| 30 | MM | 0 | Abs | PR | Na | PR (320) | — |
| 31 | MM | 2* | lim | CR | Na | CR (280) | — |
| 32 | MM | 0 | Abs | PR | Na | CR (260) | — |
| 33 | MM | 2† | Ext | SD | Na | PD (230) | — |
| 34 | AML | 0 | Na | PD | Na | Dead (66) | Leukemia |
| 35 | AML | 0 | Ext | CR | — | CR (680) | — |
| 36 | AML | 0 | Abs | CR | — | CR (230) | — |
| 37 | APL | 1 | Abs | CR | Neg | PD/MD (300) | — |
| 38 | AML | 4* | Ext | PD | Na | CR (160) | — |
| 39 | ALL | 2 | Abs | CR | Neg | CR/MR (750) | — |
| 40 | RAEBt | 3† | Ext | CR | — | Dead (650) | Leukemia |
| 41 | RAEBt | 2 | Na | CR | — | Dead (94) | CNS toxop |
| 42 | RAEBt | 2 | Abs | CR | — | CR (760) | — |
| 43 | RAEBt/CLL | 1 | Abs | CR | CLL neg | RAEBt/CR (445) | |
| CLL/CR/MR | — | ||||||
| 44 | RAEBt/MM | 1 | Abs | CR | — | Dead (500) | Leukemia |
| 45 | RAEBt | na | na | na | na | Dead (24) | Encephalytis |
| Patient . | Diagnosis . | Acute GVHD grade . | Chronic GVHD . | Status d +60 . | MRD d +60 . | Current status/PCR (d) . | Cause of death . |
|---|---|---|---|---|---|---|---|
| 1 | CLL | 1 | Abs | PR | NA | PD (700) | — |
| 2 | CLL | 1 | Lim | CR | Pos | CR/MD (310) | — |
| 3 | CLL | 0 | Abs | CR | Na | CR/MR (130) | — |
| 4 | CLL | 2 | Lim | CR | Neg | CR/MR (380) | — |
| 5 | Waldens | 0 | Abs | SD | NA | SD (220) | — |
| 6 | MZL | 3 | Ext | PR | NA | Dead (234) | Pneumonia/GVHD |
| 7 | FCL | 0 | Abs | CR | Neg | CR/MR (755) | — |
| 8 | FCL | 2 | Abs | CR | Neg | CR/MR (510) | — |
| 9 | FCL | 2* | Ext | CR | Pos | CR/MR (485) | — |
| 10 | MCL | 2 | Abs | PR | Na | Dead (188) | Lymphoma |
| 11 | MCL | 2 | Ext | PR | Na | Dead (698) | Lymphoma |
| 12 | MCL | 3 | Ext | PR | Na | CR (160) | — |
| 13 | MCL | 2 | Ext | CR | Neg | CR/MR (850) | — |
| 14 | DLCL | 1 | Lim | CR | Neg | CR/MR (735) | — |
| 15 | DLCL | 0 | Abs | CR | — | CR (220) | — |
| 16 | DLCL | 1 | Abs | CR | — | PD (490) | — |
| 17 | DLCL | 1 | Abs | CR | — | CR (440) | — |
| 18 | T cell | 2 | Abs | CR | — | CR (340) | — |
| 19 | DLCL | 2 | Na | NA | Na | Dead (69) | TTP |
| 20 | DLCL | 0 | Abs | CR | Na | CR (180) | — |
| 21 | BL | 0 | Abs | CR | Neg | CR/MR (250) | — |
| 22 | DLCL | 1 | Na | PR | Na | Dead (95) | Lymphoma |
| 23 | DLCL | 2 | Lim | CR | — | CR (850) | — |
| 24 | DLCL | 1 | Lim | CR | Neg | CR/MR (850) | — |
| 25 | HD | 1 | Lim | SD | Na | Dead (240) | Hodgkin |
| 26 | HD | 0 | Abs | PD | Na | PD (170) | — |
| 27 | HD | 0 | Ext | SD | Na | PD (600) | Hodgkin |
| 28 | HD | 2* | Lim | CR | — | CR (410) | — |
| 29 | MM | 4 | Ext | PR | Na | Dead (140) | GVHD |
| 30 | MM | 0 | Abs | PR | Na | PR (320) | — |
| 31 | MM | 2* | lim | CR | Na | CR (280) | — |
| 32 | MM | 0 | Abs | PR | Na | CR (260) | — |
| 33 | MM | 2† | Ext | SD | Na | PD (230) | — |
| 34 | AML | 0 | Na | PD | Na | Dead (66) | Leukemia |
| 35 | AML | 0 | Ext | CR | — | CR (680) | — |
| 36 | AML | 0 | Abs | CR | — | CR (230) | — |
| 37 | APL | 1 | Abs | CR | Neg | PD/MD (300) | — |
| 38 | AML | 4* | Ext | PD | Na | CR (160) | — |
| 39 | ALL | 2 | Abs | CR | Neg | CR/MR (750) | — |
| 40 | RAEBt | 3† | Ext | CR | — | Dead (650) | Leukemia |
| 41 | RAEBt | 2 | Na | CR | — | Dead (94) | CNS toxop |
| 42 | RAEBt | 2 | Abs | CR | — | CR (760) | — |
| 43 | RAEBt/CLL | 1 | Abs | CR | CLL neg | RAEBt/CR (445) | |
| CLL/CR/MR | — | ||||||
| 44 | RAEBt/MM | 1 | Abs | CR | — | Dead (500) | Leukemia |
| 45 | RAEBt | na | na | na | na | Dead (24) | Encephalytis |
After cyclosporine withdrawal.
After DLI.
CLL indicates chronic lymphocytic leukemia; MZL, marginal zone lymphoma; FCL, follicular cell lymphoma; MCL, mantle cell lymphoma; DLCL, diffuse large cell lymphoma; BL, Burkitt lymphoma; HD, Hodgkin disease; MM, multiple myeloma; AML, acute myeloid leukemia; APL, acute promyelocytic leukemia; ALL, acute lymphocytic leukemia; RAEBt, refractory anemia with excess of blasts in transformation; Abs, absent; Lim, limited; Ext, extensive; PR, partial remission; CR, complete remission; SD, stable disease; PD, progressive disease; MD, molecular disease; MR, molecular remission; CNS, central nervous system; TTP, thrombotic thrombocytopenic purpura; Toxop, toxoplasmosis; Waldens, lymphoplasmacytoid lymphoma; and MRD, minimal residual disease.